Company intelligence / Profile preview
Suzhou Ruihe Pharmaceutical Technology
Suzhou, Jiangsu, China
- Ownership
- Private
- Development stage
- Other
01
Overview
Suzhou Ruihe Pharmaceutical Technology develops peptide-conjugated radionuclide therapeutics targeting PSMA in prostate cancer, including 177Lu-PSMA-0057 (early Phase 1) and [68Ga]-PSMA-0057 (IND approval) with primary indications in metastatic prostatic adenocarcinoma and PSMA-positive prostatic cancer. Clinical results and broader data are not publicly available.[3][10]
- Therapeutic areas
- Oncology
- Modalities
- Therapeutic radiopharmaceuticalPeptide Conjugate Radionuclide
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
Jiangsu Provincial People's Hospital
Beyond the preview
Go deeper on Suzhou Ruihe Pharmaceutical Technology.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Suzhou Ruihe Pharmaceutical Technology.